FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1509-1511 October 2, 2008 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Gulick, R. M. Related Article by Fätkenheuer, G. PubMed Citation

The development of new drugs against human immunodeficiency virus type 1 (HIV-1) has resulted in combination therapy that can inhibit various steps of viral replication. Maraviroc is an example of a new class of such drugs that have a novel mechanism of action against HIV-1.¹ Maraviroc binds to the human chemokine receptor 5 (CCR5), which also serves as a coreceptor for a major phenotype of HIV-1, R5 tropic virus, and thereby interferes with an essential early step in viral replication. Maraviroc has shown activity both in vitro and in vivo against R5 HIV-1 strains. In two large-scale trials reported in . . . [Full Text of this Article]

This article has been cited by other articles:

• (2008). Maraviroc: Phase III Studies Published. JWatch Infect. Diseases 2008: 1-1 [Full Text]